Results 101 to 110 of about 898 (115)

Iptacopan for paroxysmal nocturnal haemoglobinuria. [PDF]

Aust Prescr
europepmc   +1 more source

Response to the Letter to the Editor Entitled "Defining "Dominance" in Atypical Hemolytic Uremic Syndrome: Distinguishing Amplification From Initiation". [PDF]

Kidney Int Rep
Aiello S, Santarsiero D, Gastoldi S, Benigni A, Remuzzi G, Noris M.   +5 more
europepmc   +1 more source

Advances in Complement Inhibition Therapies for Paroxysmal Nocturnal Hemoglobinuria and Autoimmune Hemolytic Disorders. [PDF]

J Blood Med
Tamdin T, Rodgers GM.
europepmc   +1 more source

Bioorthogonal tuning of nanosurface opsonisation <i>via</i> click coupling of a complement fusion protein inhibitor.

Chem Commun (Camb)
Jacques S, Gaikwad H, Pillatzke J, Moghimi SM, Simberg D.   +4 more
europepmc   +1 more source

Alternative Complement Pathway Inhibition With Iptacopan for the Treatment of C3 Glomerulopathy-Study Design of the APPEAR-C3G Trial [PDF]

Kidney International Reports, 2022
\ua9 2022Introduction: Complement 3 glomerulopathy (C3G) is a rare kidney disease characterized by dysregulation of the alternative pathway (AP) of the complement system.
Andrew Bomback, Marina Vivarelli, Richard Smith   +2 more
exaly   +5 more sources

Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy

New England Journal of Medicine
Background The alternative complement pathway plays a key role in the pathogenesis of IgA nephropathy. Iptacopan specifically binds to factor B and inhibits the alternative pathway.
Dmitrij Kollins, Olympia Papachristofi
exaly   +6 more sources

Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 study [PDF]

Lancet, The
Background: C3 glomerulopathy (C3G) is an ultra-rare, severe form of glomerulonephritis caused by overactivation of the alternative complement pathway (AP). Iptacopan (LNP023) is an oral, proximal complement inhibitor that targets Factor B to selectively
Dharmendra Bhadauria, François Provôt, Dinesh Khullar   +2 more
exaly   +7 more sources

Design and Rationale of the APPELHUS Phase 3 Open-Label Study of Factor B Inhibitor Iptacopan for Atypical Hemolytic Uremic Syndrome

Kidney International Reports, 2023
Atypical hemolytic uremic syndrome (aHUS) is a rare, progressive, and life-threatening form of thrombotic microangiopathy (TMA) which is caused by dysregulation of the alternative complement pathway (AP). Complement inhibition is an effective therapeutic
Fadi Fakhouri, Larry Greenbaum, Arvind Bagga   +2 more
exaly   +2 more sources

Successful Management of C3 Glomerulopathy Recurrence Post-Kidney Transplantation with Iptacopan: A Case Report

International Journal of Molecular Sciences
C3 glomerulopathy (C3G) is the predominant cause of complement-mediated membranoproliferative glomerulonephritis and is considered a rare disorder caused by genetic or acquired dysregulation of the alternative complement pathway. There are no established
Giovanni Stallone, Loreto Gesualdo, Michele Rossini   +2 more
exaly   +2 more sources